Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIK-RO: Alpelisib Roll-over Study
NCT07679269Phase 2Not yet recruiting
- Sponsor
- Novartis
- Start
- Dec 2026
- Primary completion
- Mar 2032
01
Overview
A Phase 2 trial of alpelisib in PIK3CA-related overgrowth spectrum (PROS), breast cancer, sponsored by Novartis. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
alpelisib
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)breast cancer
Beyond the preview
Go deeper on NCT07679269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07679269.